Journal article
Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study
- Abstract:
-
Background Many patients with psoriatic arthritis do not reach minimal disease activity (MDA) on methotrexate alone. This phase 4 open-label study aimed to compare attainment of MDA following introduction of adalimumab with methotrexate escalation in patients with psoriatic arthritis who do not reach MDA after an initial methotrexate course (≤15 mg every week). Methods CONTROL was a phase 4, randomised, two-part, open-label study conducted in 14 countries and 46 sites. We recruited patients ...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.2MB, Terms of use)
-
- Publisher copy:
- 10.1016/S2665-9913(22)00008-X
Authors
Bibliographic Details
- Publisher:
- Elsevier
- Journal:
- Lancet Rheumatology More from this journal
- Volume:
- 4
- Issue:
- 4
- Pages:
- E262-E273
- Publication date:
- 2022-02-25
- Acceptance date:
- 2022-01-07
- DOI:
- EISSN:
-
2665-9913
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
1232827
- Local pid:
-
pubs:1232827
- Deposit date:
-
2022-01-17
Terms of use
- Copyright holder:
- Coates et al.
- Copyright date:
- 2022
- Rights statement:
- © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record